Literature DB >> 17007731

Proliferative vitreoretinopathy: developments in pathogenesis and treatment.

Riaz H Y Asaria1, David G Charteris.   

Abstract

Proliferative vitreoretinopathy is an abnormal wound-healing response following retinal detachment and occurs in 5% to 10% of cases. It is now possible to treat this once-blinding condition. However, proliferative vitreoretinopathy still remains the most common cause of failure to reattach the retina. Recent work has helped to unravel the causes of proliferative vitreoretinopathy, and new adjuvant treatments are being evaluated to improve the success rate of retinal reattachment surgery, both anatomically and functionally. At present, preventative treatment has only been found to work in high-risk cases. It is hoped that improvement in targeted immunosupression will eventually reduce the incidence of proliferative vitreoretinopathy. At the current time, the management of proliferative vitreoretinopathy still remains a surgical skill.

Entities:  

Mesh:

Year:  2006        PMID: 17007731

Source DB:  PubMed          Journal:  Compr Ophthalmol Update        ISSN: 1527-7313


  16 in total

1.  Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Authors:  Steven Pennock; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2014-09-26       Impact factor: 4.307

Review 2.  Rhegmatogenous retinal detachment--an ophthalmologic emergency.

Authors:  Nicolas Feltgen; Peter Walter
Journal:  Dtsch Arztebl Int       Date:  2014-01-06       Impact factor: 5.594

3.  RasGAP Promotes Autophagy and Thereby Suppresses Platelet-Derived Growth Factor Receptor-Mediated Signaling Events, Cellular Responses, and Pathology.

Authors:  Hetian Lei; Cynthia X Qian; Jinghu Lei; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 4.272

4.  Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR).

Authors:  David G Telander; Shawn A Morales; Sergey Mareninov; Krisztina Forward; Lynn K Gordon
Journal:  Curr Eye Res       Date:  2011-06       Impact factor: 2.424

5.  Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 expression in murine experimental retinal detachment.

Authors:  Bongsu Kim; Mohamed H Abdel-Rahman; Tiffany Wang; Severin Pouly; Ashraf M Mahmoud; Colleen M Cebulla
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-03       Impact factor: 4.799

6.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

7.  Inhibition of TGF-β2-induced migration and epithelial-mesenchymal transition in ARPE-19 by sulforaphane.

Authors:  Yan-Bing Huang; Ping-Ping Liu; Hui Zheng; Xiu-Xia Yang; Cheng-Cheng Yang; Ye Liu; Yang Liu
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

Review 8.  Epithelial phenotype and the RPE: is the answer blowing in the Wnt?

Authors:  Janice M Burke
Journal:  Prog Retin Eye Res       Date:  2008-08-19       Impact factor: 21.198

9.  A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.

Authors:  Mei Chen; Jiangping Hou; Guilin Tan; Peng Xie; William R Freeman; James R Beadle; Karl Y Hostetler; Lingyun Cheng
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  Retinal Pigment Epithelium and Müller Progenitor Cell Interaction Increase Müller Progenitor Cell Expression of PDGFRα and Ability to Induce Proliferative Vitreoretinopathy in a Rabbit Model.

Authors:  Gisela Velez; Alexa R Weingarden; Budd A Tucker; Hetian Lei; Andrius Kazlauskas; Michael J Young
Journal:  Stem Cells Int       Date:  2012-08-23       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.